Serotonergic receptor subtypes and hallucinogen-induced stimulus control.
Jerrold C Winter, David Fiorella, D M Timineri, R A Filipink, Scott Helsley, R A Rabin
Pharmacology, Biochemistry, and Behavior October 1999 DOI: 10.1016/s0091-3057(99)00063-5 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Serotonin |
| Key findings | Argues that hallucinogens produce compound discriminative stimuli through actions at multiple serotonin receptors, with the salience of each component modulated by training dose, pretreatment time, sensitization state, and generalization test drugs. |
Abstract
More than a quarter century has passed since the demonstration that indoleamine and phenethylamine hallucinogens can function as discriminative stimuli in the rat, and that serotonergic systems are critically involved. During that period our knowledge of the physiology, pharmacology, biochemistry, and molecular biology of serotonergic receptors has increased exponentially; with each advance it has been necessary to reexamine our assumptions regarding hallucinogen-induced stimulus control. Of particular interest is the hypothesis that a drug may act, at a molecular level, upon multiple receptors to produce, at a behavioral level, a compound discriminative stimulus. The salience of the individual elements of such compound stimuli may be influenced by a variety of experimental factors including training dose, pretreatment time, the state of sensitization of the systems being acted upon, and the nature of the drugs chosen for tests of generalization. This article provides examples of experimental approaches to these complexities using selective agonists and antagonists, depletion-induced sensitization, and antagonist correlation analysis.
Comparable studies
Other narrative reviews on serotonin, most cited first.
Citations in the library
Cited by 21
- Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Current Drug Metabolism October 1, 2010
- Animal Models of Serotonergic Psychedelics ACS Chemical Neuroscience September 24, 2012
- The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs. The International Journal of Neuropsychopharmacology August 1, 2014
- Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions The AAPS Journal May 3, 2008
- Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics February 1, 2008
and 16 more in the library
Cites 14
- Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences December 17, 1984
- Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. Journal of Pharmacology and Experimental Therapeutics September 1, 1988
- Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans Biological Psychiatry May 1, 1996
- EFFECTS OF MESCALINE AND LYSERGIC ACID (d-LSD-25) American Journal of Psychiatry February 1, 1952
- The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors. Pharmacology, Biochemistry, and Behavior 2000
and 9 more in the library